Tumour Angiogenesis Regulation by the Mir-200 Family
Chad V. Pecot,Rajesha Rupaimoole,Da Yang,Rehan Akbani,Cristina Ivan,Chunhua Lu,Sherry Wu,Hee-Dong Han,Maitri Y. Shah,Cristian Rodriguez-Aguayo,Justin Bottsford-Miller,Yuexin Liu,Sang Bae Kim,Anna Unruh,Vianey Gonzalez-Villasana,Li Huang,Behrouz Zand,Myrthala Moreno-Smith,Lingegowda S. Mangala,Morgan Taylor,Heather J. Dalton,Vasudha Sehgal,Yunfei Wen,Yu Kang,Keith A. Baggerly,Ju-Seog Lee,Prahlad T. Ram,Murali K. Ravoori,Vikas Kundra,Xinna Zhang,Rouba Ali-Fehmi,Ana-Maria Gonzalez-Angulo,Pierre P. Massion,George A. Calin,Gabriel Lopez-Berestein,Wei Zhang,Anil K. Sood
DOI: https://doi.org/10.1038/ncomms3427
IF: 16.6
2013-01-01
Nature Communications
Abstract:The miR-200 family is well known to inhibit the epithelial-mesenchymal transition, suggesting it may therapeutically inhibit metastatic biology. However, conflicting reports regarding the role of miR-200 in suppressing or promoting metastasis in different cancer types have left unanswered questions. Here we demonstrate a difference in clinical outcome based on miR-200's role in blocking tumour angiogenesis. We demonstrate that miR-200 inhibits angiogenesis through direct and indirect mechanisms by targeting interleukin-8 and CXCL1 secreted by the tumour endothelial and cancer cells. Using several experimental models, we demonstrate the therapeutic potential of miR-200 delivery in ovarian, lung, renal and basal-like breast cancers by inhibiting angiogenesis. Delivery of miR-200 members into the tumour endothelium resulted in marked reductions in metastasis and angiogenesis, and induced vascular normalization. The role of miR-200 in blocking cancer angiogenesis in a cancer-dependent context defines its utility as a potential therapeutic agent.